أستونيا - الإستونية - Ravimiamet

norgine b.v. - makrogool+naatriumsulfaat, veevaba+naatriumkloriid+kaaliumkloriid+askorbiinhape+naatriumaskorbaat - suukaudse lahuse pulber - 100g+7,5g+2,691g+1,015g+0+0/0+0+0+0+4,7g+5,9g 640tk / 640tk; 100g+7,5g+2,691g+1,015g+0+0/0+0+0+0+4,7g+5,9g 20tk / 20tk; 100g+7,5g+2,691g+1,015g+0+0/0+0+0+0+4,7g+5,9g 2tk / 2tk; 100g+7,5g+2,691g+1,015g+0+0/0+0+0+0+4,7g+5,9g 320tk / 320tk; 100g+7,5g+2,691g+1,015g+0+0/0+0+0+0+4,7g+5,9g 160tk / 160tk

أستونيا - الإستونية - Ravimiamet

mip pharma gmbh - makrogool+naatriumtsitraat+sidrunhape+naatriumkloriid+kaaliumkloriid - suukaudse lahuse kontsentraat - 525mg+19,5mg+16,5mg+7,3mg+1,9mg 1ml 100ml 1tk; 525mg+19,5mg+16,5mg+7,3mg+1,9mg 1ml 500ml 1tk; 525mg+19,5mg+16,5mg+7,3mg+1,9mg 1ml 1000ml 1tk; 525mg+19,5mg+16,5mg+7,3mg+1,9mg 1ml 200ml 1tk

أستونيا - الإستونية - Ravimiamet

tillotts pharma ab - makrogool+naatriumkloriid+naatriumvesinikkarbonaat+kaaliumkloriid - suukaudse lahuse pulber - 105g+2,8g+1,43g+0,37g 4tk

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

incline therapeutics europe ltd - fentanüülvesinikkloriid - valu, postoperatiivne - valuvaigistid - täiskasvanud patsientidel on ionsys näidustatud ägeda mõõduka kuni raske postoperatiivse valu raviks.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degareliks - eesnäärmevähk - endokriinset ravi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - sclerosis multiplex, relapsing-remitting - immunosupressandid - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mitu müeloomit - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

intervet international b. v. - tepoksaliin - lihas-skeleti süsteem - koerad - põletiku vähendamine ja valu leevendamine, mida põhjustavad ägedad ja kroonilised luu- ja lihaskonna häired.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

bayer ag - radium (223ra) dichloride - eesnäärmevähk - terapeutilised radiofarmatseutilised ühendid - xofigo on näidustatud kastreeruva resistentsusega eesnäärmevähiga täiskasvanute, sümptomaatiliste luu metastaaside raviks ja teadaolevate vistseraalsete metastaaside puudumisel.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatic kasvajad, kastreerimine-vastupidavad - antineoplastilised ained - treatment of adult patients with prostate cancer.